Vaborbactam

Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.

Vaborbactam
Clinical data
Routes of
administration		IV
ATC code
  • None
Identifiers
  • {(3R,6S)-2-Hydroxy-3-[2-(thiophen-2-yl)acetamido]-
    1,2-oxaborinan-6-yl}acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ECHA InfoCard100.235.136
Chemical and physical data
FormulaC12H16BNO5S
Molar mass297.13 g·mol−1
3D model (JSmol)
  • B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
  • InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
  • Key:IOOWNWLVCOUUEX-WPRPVWTQSA-N

In the United States, the combination drug meropenem/vaborbactam (Vabomere) is approved by the Food and Drug Administration for complicated urinary tract infections and pyelonephritis.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.